Evidence-Based Medicine Guidelines
Trimethoprim or trimethoprim-sulfamethoxazole and risk of hyperkalaemia among patients taking renin-angiotensin system blockers
Trimethoprim or trimethoprim-sulfamethoxazole and risk of hyperkalaemia among patients taking renin-angiotensin system blockers is a topic covered in the Evidence-Based Medicine Guidelines.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Trimethoprim or Trimethoprim-sulfamethoxazole and Risk of Hyperkalaemia Among Patients Taking Renin-angiotensin System Blockers." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/1305285/all/Trimethoprim_or_trimethoprim_sulfamethoxazole_and_risk_of_hyperkalaemia_among_patients_taking_renin_angiotensin_system_blockers.
Trimethoprim or trimethoprim-sulfamethoxazole and risk of hyperkalaemia among patients taking renin-angiotensin system blockers. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305285/all/Trimethoprim_or_trimethoprim_sulfamethoxazole_and_risk_of_hyperkalaemia_among_patients_taking_renin_angiotensin_system_blockers. Accessed December 3, 2022.
Trimethoprim or trimethoprim-sulfamethoxazole and risk of hyperkalaemia among patients taking renin-angiotensin system blockers. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305285/all/Trimethoprim_or_trimethoprim_sulfamethoxazole_and_risk_of_hyperkalaemia_among_patients_taking_renin_angiotensin_system_blockers
Trimethoprim or Trimethoprim-sulfamethoxazole and Risk of Hyperkalaemia Among Patients Taking Renin-angiotensin System Blockers [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2022 December 03]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/1305285/all/Trimethoprim_or_trimethoprim_sulfamethoxazole_and_risk_of_hyperkalaemia_among_patients_taking_renin_angiotensin_system_blockers.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Trimethoprim or trimethoprim-sulfamethoxazole and risk of hyperkalaemia among patients taking renin-angiotensin system blockers
ID - 1305285
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/1305285/all/Trimethoprim_or_trimethoprim_sulfamethoxazole_and_risk_of_hyperkalaemia_among_patients_taking_renin_angiotensin_system_blockers
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
